SELLAS Life Sciences Group, Inc.
Andrew Elnatan has a strong background in regulatory affairs, with a focus on the biotechnology and pharmaceutical industries. Andrew is currently working as the Vice President of Regulatory Affairs, CMC & Quality at SELLAS Life Sciences Group, Inc. since January 2023. Prior to this, they held the role of Vice President of Regulatory Affairs at SQZ Biotechnologies from November 2020 to January 2023.
Before joining SQZ Biotechnologies, Andrew worked at the International AIDS Vaccine Initiative (IAVI) as the Executive Director of Regulatory Affairs from February 2017 to October 2020. Andrew also held a similar position as the Executive Director of Regulatory Affairs at Celldex Therapeutics from November 2012 to February 2017.
In addition, Andrew has experience as a Director of Regulatory Affairs at Inspiration Biopharmaceuticals, Inc from September 2012 to November 2012, and at Sangart Inc from November 2010 to September 2012.
Andrew started their career at Amgen Inc in 2005, where they held various roles including Director of Regulatory Affairs from October 2007 to November 2010, Senior Manager of Development Operations from July 2006 to September 2007, and Manager of Regulatory Affairs from August 2005 to June 2006. Prior to this, they worked at Amgen Cambridge UK as a Manager of Regulatory Affairs from November 2003 to July 2005.
Andrew Elnatan attended Victorian College of Pharmacy from 1986 to 1988, where they earned a Bachelor's degree (BPharm) in Pharmacy. Andrew then pursued further education at Monash University Pharmacy College from 1990 to 1992, graduating with a Master's degree (MPharm) in Pharmacology.
This person is not in any teams
This person is not in any offices
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences AG is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications.The Company’s lead product candidate, licensed from Memorial Sloan-Kettering Cancer Center (MSKCC), is a late-stage innovative WT1-targeting synthetic heteroclitic epitopeimmunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The WT1 antigen is one of the most widely expressed cancer antigens and ranked by the National Cancer Institute (NCI) as the number 1 target for immunotherapy. Traditional approaches have not been able to address the WT1 protein, as WT1 is not druggable with small molecules and is intracellular and inaccessible to antibodies. The company has a close working relationship with MSKCC, who is also a shareholder.The Company plans to initiate a pivotal Phase III study in H1:17 in acute myeloid leukemia (AML) as well as malignant pleural mesothelioma (MPM) by H2:17 and is currently conducting Phase I and Phase II studies in ovarian cancer (combination with BMS’s nivolumab (Opdivo®) and multiple myeloma (MM) and will advance additional studies into the clinic. Phase II data in AML and MPM have shown positive safety and survival trends, with median OS in AML of 61.8 months vs. ~12-15 months for best standard treatment and median OS in MPM of 24.8 months vs.16.6 months in the control arm. Further recent data in multiple myeloma has shown an 86% overall survival rate after 18 months in patients with high-risk cytogenetics following stem cell transplantation. The US FDA granted orphan designations and fast track designations for SELLAS WT1 therapy, galinpepimut-S, for AML and MPM and the European EMA granted orphan designation for AML and MPM.Galinpepimut-S has the potential to complement currently available therapies by destroying residual tumor cells of cancers in remission and providing ongoing immune surveillance to avoid or significantly delay tumor recurrence. Its use in this setting is aided by an attractive safety profile not found in standard of care therapies.